Three Digital Health Startups Secure Combined $6.2M in Funding for Chronic Disease and Specialty Care Solutions
○ Oncora Medical Raises $1.2 Million to Help Physicians Develop Personalized Radiation Therapy Plans for Cancer Patients
○ Brain rehabilitation therapy company Constant Therapy completes $2 million Series A financing
○, Invested $3 million in Purdue University to fund the development of chronic disease healthcare management software
Oncora Medical Raises $1.2 Million to Help Physicians Develop Personalized Radiation Therapy Plans for Cancer Patients
Oncora Medical, a digital health company based in Pennsylvania, USA, announced the completion of a $1.2 million seed funding round. The round was led by iSeed Ventures, with participation from Philadelphia-based BioAdvance and renowned medical scientist and entrepreneur Dr. Thomas “Rock” Mackie. The funds raised will be used to establish a research team at Oncora Medical’s Philadelphia headquarters to collaborate with leading healthcare systems on the development of its new products.
For approximately two-thirds of cancer patients, radiation therapy is the primary treatment modality for disease control; however, inappropriate radiation therapy poses a serious threat to patients’ life and health. The software platform developed by Oncora Medica assists physicians in tailoring treatment plans and providing personalized care by collecting and leveraging data related to patients’ radiation therapy. Once all relevant patient data are automatically aggregated from cancer centers into the Oncora Medica system, they are seamlessly presented to physicians through clear visualization tools. Furthermore, each new patient’s data are matched with those of previously treated patients with similar characteristics, thereby providing robust support for clinical decision-making. Consequently, the core value of Oncora Medica’s service lies in enabling physicians to draw upon valuable historical experience to enhance the quality of future medical care.
Furthermore, physicians can review historical radiation dose data from previous patients’ radiotherapy treatments through Oncora Medica’s dose prescription system. After determining the treatment plan, systematic analysis can also predict therapeutic efficacy and associated risks. This approach ensures that patients achieve the highest possible likelihood of treatment success while minimizing risk exposure.
Thus, under the leadership of Oncora Medical, personalized cancer treatment has taken a significant step forward.
2. Brain Rehabilitation Therapy Company Constant Therapy Completes $2 Million Series A Financing
Constant Therapy is a Boston-based brain rehabilitation company whose app provides rehabilitation programs for patients with conditions such as traumatic brain injury, stroke, aphasia, and learning disabilities.
Recently, the company completed a $2 million Series A financing round, led by Golden Seeds, with participation from Kapor Capital, Launchpad Venture Group, Pond Capital, Community Health Network of Connecticut, and others. To date, Constant Therapy has raised a total of $2.7 million in funding.
Keith Cooper, CEO of the company, stated that Constant Therapy’s app was developed by leading experts in the field of global brain rehabilitation. It leverages data analytics and scientific methodologies to optimize treatment outcomes for brain injuries, providing not only personalized neurorehabilitation treatment plans for each patient but also serving as a reference for physicians during clinical practice.
Users can access the service simply by downloading its mobile app. Subscription fees are $19.99 per month, $199.90 per year, or $299.90 for three years.
AHRQ and NIH Invest $3 Million in Purdue University to Fund the Development of Chronic Disease Care Management Software
Christopher Harle, a professor in the Department of Health Care Management and Policy at Purdue University, has recently secured two grants totaling $3 million from the Agency for Healthcare Research and Quality (AHRQ) and the National Institutes of Health (NIH) to develop software for chronic disease care management.
Chronic diseases affect more than 100 million Americans, with annual national expenditures reaching $630 billion, while also contributing to workforce attrition and rising unemployment rates. Therefore, Purdue University developed this software to leverage information technology tools in safeguarding healthcare for patients with chronic conditions.
This investment serves another purpose as well: by leveraging such digital tools, we aim not only to deliver high-quality healthcare services to patients but also to help the public better understand the significance of granting clinical researchers access to their electronic health records (EHRs). “Our goal is to leverage the data within these EHRs to develop treatment support software for chronic diseases on a clinical basis,” explained Professor Christopher Harle.